Navigation Links
Idenix Pharmaceuticals Reports Second Quarter and Six Month Financial Results

hat subsequent events and developments may cause these views, expectations and beliefs to change. However, while Idenix may elect to update these forward-looking statements at some point in the future, it specifically disclaims any obligation to do so.

Idenix Pharmaceuticals' Contact:

Amy Sullivan (617) 995-9838





Three Months Ended Six Months Ended

June 30, June 30,

2008 2007 2008 2007


Collaboration revenue -

related party $1,433 $18,674 $3,478 $43,025

Other revenue 159 1,058 157 1,513

Total revenues 1,592 19,732 3,635 44,538

Operating expenses (1):

Cost of sales 415 167 810 237

Research and

development 14,136 24,570 29,004 47,124

Selling, general and

administrative 6,651 19,837 14,972 35,677

Restructuring charges 37 ------ 297 ------

Total operating

expenses 21,239 44,574 45,083 83,038

Loss from operations (19,647) (24,842) (41,448) (38,500)

Investment income and

other income, net 485 1,802 1,425 3,780

Loss before income taxes (19,162) (23,040) (40,023) (34,720)

Income tax benefit 256 138 657 249

Net loss $(18,906) $(22,902) $(39,

SOURCE Idenix Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related biology technology :

1. Idenix Pharmaceuticals to Present at the Seventh Annual Needham and Company, LLC Biotechnology and Medical Technology Conference
2. Idenix Pharmaceuticals to Present at the Rodman & Renshaw 5th Annual Global Healthcare Conference
3. Idenix Pharmaceuticals to Present at the Morgan Stanley Global Healthcare Unplugged Conference
4. Idenix Announces Data Presentations at the 43rd Annual Meeting of the European Association for the Study of the Liver (EASL)
5. Idenix to Host Conference Call Discussing Fourth Quarter 2007 Financial Results
6. Idenix Pharmaceuticals to Present at BIO CEO & Investor Conference
7. Idenix to Host Conference Call Discussing Third Quarter 2007 Financial Results
8. Idenix Pharmaceuticals Restructures to Concentrate Efforts on HCV and HIV Programs
9. Poniard Pharmaceuticals to Host Second Quarter 2008 Financial Results Conference Call on July 31
10. Sagent Pharmaceuticals Launches Ceftazidime for Injection, USP
11. Peregrine Pharmaceuticals Receives Letter from NASDAQ Citing Failure to Regain Compliance with Minimum Bid Price Rule
Post Your Comments:
(Date:10/8/2015)... , Oct. 8, 2015  Today the Wyss Institute ... launch of its start-up company Opsonix Inc. ... Harvard,s Office of Technology Development (OTD) and ... sepsis therapy for clinical use. ... least a million people every year in the U.S. ...
(Date:10/8/2015)... TORONTO, CANADA (PRWEB) , ... October 08, 2015 ... ... it has entered into an exclusive license agreement to develop and commercialize intellectual ... expands upon the original agreement from February 2009, and affords exclusive worldwide rights ...
(Date:10/7/2015)... 7, 2015 Boston Scientific (NYSE: ... the Boston Scientific Connected Patient Challenge , an ... use of remote patient monitoring to enhance patient care.  ... can submit their ideas and collaborate on solutions through ... Cambridge, MA where they ...
(Date:10/7/2015)... 7, 2015  ChromaDex Corp. (OTCQX: CDXC), an ... that creates science-based solutions for dietary supplement, food ... products, today announced that the October 1 presentation ... is now available for on-demand viewing at ...   --> LINK: ...
Breaking Biology Technology:
... BOONTON, N.J. and BRUSSELS, Sept. 24 Tarsa ... Board: UGNE ) today reported preclinical ... in combination with other drugs in reducing the ... being presented at the 2010 Osteoarthritis Research Society ...
... While scientists have spent the past 40 years describing ... mammalian cell divides into two, they still haven,t agreed ... seemingly contradictory theories, which now may be reconciled by ... Lingchong You. These findings could provide insights into the ...
... Scarguard Labs, LLC, announced achieving the combined ranking of the ... the category according to Information Resources, Inc.,s data ending August 8, ... the prior year for the four week period ending August 8, ... based on dollar sales for the same four week period. ...
Cached Biology Technology:
(Date:10/6/2015)... , Oct. 6, 2015 Track Group, ... today that it has signed a contract with the ... across the full range of sentences under the Department,s ... of the Americas. "This contract with the Virginia DOC ... the US and advances our position as a trusted ...
(Date:10/5/2015)... 5, 2015 ) ... NXT-ID, Inc. (NASDAQ: NXTD ), a biometric authentication ... --> ) releases the following ... NXTD ), a biometric authentication company focused on the ... Group ( ) releases the following ...
(Date:10/1/2015)... 2015  Biometrics includes diverse set of technologies ... such as fingerprints, eye retinas, facial patterns, voice ... technology has been constantly increasing in ... In addition to the most prominent popular method ... means of biometric authentication are rapidly gaining traction ...
Breaking Biology News(10 mins):
... vaccine principle is being developed by scientists at the University ... expected potential could help to save millions of lives ... is known, represents an advance on the original DNA vaccines ... consists of a chain of amino acids attached to a ...
... researcher Dr. Danny Reinberg was awarded a Howard Hughes ... on ant epigenetics- helping to unravel the impact lifestyle ... what ants can teach us about aging and behavior. ... species including humans, using gene regulation in ants as ...
... probably the largest contaminant of our body. That this ... has not been proven convincingly. The current Editorial of ... reflects on this and concludes that this proof ... take measures to reduce our exposure from all ...
Cached Biology News:
... for all types of yeast two-hybrid studies, including complex ... Choice of two bait vectors for maximum ... Triple reporter strain NMY51 ... Complete set of controls: pLexA-p53, pLexA-lamin ...
... Quickly, effectively seals labware. Waterproof, ... protects anhydrous materials. Can be folded ... without rupturing. Stretched lengthwise at 21C ... Yet when tension is removed, film ...
Human Serum FDA Licensed US Donor Centers Sterile / Non-sterile: Sterile Filtered to 0.2 micron Information: Extensive Viral Testing ...
Normal human serum collected off the clot from healthy normal humans. Each donor unit is negative for anti-HIV 1&2, HIV-Ag, HCV, and HBsAg by FDA required tests...
Biology Products: